| Structure | Cat No. | Product Name | CAS No. | Product Description |
|---|---|---|---|---|
|
V1869 | BAY 41-2272 | 256376-24-6 | BAY 41-2272 is a novel and potent activator of nitric oxide-sensitive guanylyl cyclase (NO-sensitive GC) with EC50 values of 0.3 μmol/L and 3 μmol/L in the presence and absence of 100 nmol/L DEA-NO, respectively. |
|
V4214 | Cinaciguat HCl | 646995-35-9 | Cinaciguat HCl, the hydrochloride salt of Cinaciguat (formerly also known as BAY582667 or BAY58-2667), is a novel and potent activator of soluble guanylate cyclase (sGC) used for acute decompensated heart failure. |
|
V86637 | Formycin triphosphate | 16409-13-5 | Formycin triphosphate is a fluorescent analog of ATP that exhibits enhanced fluorescence upon binding to the enzyme active site. |
|
V74641 | MM419447 | 1092457-78-7 | MM 419447, a linaclotide metabolite, is a guanylate cyclase-C agonist. |
|
V74639 | Mosliciguat (BAY 1237592) | 2231749-54-3 | Mosliciguat is a guanylate cyclase activator. |
|
V111569 | S-3448 | 254877-04-8 | S-3448 is a derivative of atasciguat and a soluble guanylate cyclase (sGC) agonist. |
|
V146808 | Uroguanylin (human) TFA | Uroguanylin (human) TFA is a natural ligand for the guanylate cyclase (GCC) receptor expressed in metastatic colorectal cancer tumors. | |
|
V1868 | Riociguat (BAY 63-2521) | 625115-55-1 | Riociguat (formerly also known as BAY-63-2521, BAY-632521; trade name Adempas) is a first-in-class and oral bioavailable soluble guanylate cyclase (GC) stimulator that has been approved to treat two forms of pulmonary hypertension (PH): chronic thromboembolic pulmonary hypertension (CTEPH) and pulmonary arterial hypertension (PAH). |
|
V33986 | Plecanatide acetate | 1075732-84-1 | Plecanatide acetate, the acetate salt of plecanatide, is a guanylate cyclase-C (GC-C) receptor agonist with anti-inflammatory activity. In T84 cells, it activates GCC with an EC50 of 190 nM. |